A Rare Agreement: Both Sides of US Politics Target Pharmacy Middlemen

In the United States, political disagreement is common. However, a growing number of people from both major political parties have found a shared target for their frustration: Pharmacy Benefit Managers, or PBMs. These companies act as middlemen in the healthcare system, managing prescription drug plans for insurance companies and employers. While they were originally created to help lower drug costs, many Americans now view them as a primary reason for rising prices and limited choices at the pharmacy.

According to KFF Health News, the frustration is felt by families across the country, including in Tennessee. Amye and Charlie Joseph, a married couple with different political views, both feel that the current system is unfair. They are particularly unhappy with CVS Health, a large company that owns a major health insurer, a large pharmacy chain, and one of the largest PBMs in the country. For the Josephs, the system feels less like a helpful service and more like a way for large corporations to make extra money at the expense of patients.

One of the main complaints involves the lack of choice. Many patients feel forced to use specific pharmacies owned by their PBM rather than their local, independent pharmacy. Charlie Joseph, a retired fire captain, noted that he could actually save money on his blood pressure medication by paying cash at a local pharmacy instead of using his insurance plan. This lack of consistency and transparency has led to widespread anger among consumers who feel the healthcare market is no longer working as it should.

Experts who study drug pricing suggest that this issue has created a rare moment of unity in Washington, D.C. Antonio Ciaccia, the CEO of 46brooklyn Research, a group that tracks drug prices, explained that even conservative, business-friendly lawmakers are starting to question the industry. These Republicans argue that the current market for prescription drugs is not a true free market because competition is being blocked. They are now working alongside Democrats, who have traditionally supported more government regulation, to change how these companies operate.

In response to these concerns, states across the country have begun to pass new laws to restrict the power of PBMs. Some states are even considering laws that would prevent companies from owning both a PBM and a traditional pharmacy at the same time. This legislative push shows that lawmakers are feeling the pressure from voters who are tired of high costs and confusing insurance rules.

However, the PBM industry strongly disagrees with these criticisms. Representatives for the industry argue that they are being unfairly blamed for problems they did not create. Greg Lopes, a spokesperson for the Pharmaceutical Care Management Association, which represents PBMs, stated that his industry is actually the only part of the supply chain working to lower drug costs. He suggested that PBMs are being targeted by powerful groups, such as large pharmaceutical manufacturers, who want to shift the blame for high prices away from themselves.

CVS Health also defended its business model. A company spokesperson, Phil Blando, said that looking at the price of a single drug does not show the full value of a pharmacy benefit plan. He stated that the company remains focused on delivering the lowest possible total cost and the best overall value for its members and the organizations that pay for the plans.

Despite these defenses, the political momentum against PBMs continues to grow. As healthcare costs remain a top concern for American families, the debate over the role of these middlemen is likely to continue. Whether through new state laws or federal action, the future of how prescription drugs are priced and distributed in the United States is facing significant change. For now, the PBM industry remains in the spotlight as both sides of the political aisle work to address the frustrations of patients like the Josephs.